Logo

Respiratory Syncytial Virus Infections Cochrane Pediatric Emergency Medicine Reviews

Browse Cochrane Pediatric Emergency Medicine Reviews
Browse Cochrane Pediatric Emergency Medicine Reviews

Cochrane Systematic Review: Heliox inhalation therapy for bronchiolitis in infants

Cochrane Systematic Review: Heliox inhalation therapy for bronchiolitis in infants

Visit

Liet JM, Ducruet T, Gupta V, Cambonie G.

Liet JM, Ducruet T, Gupta V, Cambonie G.

Objectives: To assess heliox in addition to standard medical care for acute bronchiolitis in infants.

Objectives: To assess heliox in addition to standard medical care for acute bronchiolitis in infants.

Cochrane Systematic Review: Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children

Cochrane Systematic Review: Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children

Visit

Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B.

Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B.

Objectives: To assess the effectiveness and safety of palivizumab prophylaxis compared with placebo, or another type of prophylaxis, in reducing the risk of complications (hospitalisation due to RSV infection) in high-risk infants and children. To assess the cost-effectiveness (or cost-utility) of palivizumab prophylaxis compared with no prophylaxis in infants and children in different risk groups.

Objectives: To assess the effectiveness and safety of palivizumab prophylaxis compared with placebo, or another type of prophylaxis, in reducing the risk of complications (hospitalisation due to RSV infection) in high-risk infants and children. To assess the cost-effectiveness (or cost-utility) of palivizumab prophylaxis compared with no prophylaxis in infants and children in different risk groups.

Cochrane Systematic Review: Ribavirin for respiratory syncytial virus infections of the lower respiratory tract in infants and young children

Cochrane Systematic Review: Ribavirin for respiratory syncytial virus infections of the lower respiratory tract in infants and young children

Visit

Ventre K, Randolph A.

Ventre K, Randolph A.

Objectives: The objective of this review is to assess the efficacy of aerosolized ribavirin for infants and children with lower respiratory tract infections due to RSV.

Objectives: The objective of this review is to assess the efficacy of aerosolized ribavirin for infants and children with lower respiratory tract infections due to RSV.

Cochrane Systematic Review: Antibiotics for persistent cough or wheeze following acute bronchiolitis in children

Cochrane Systematic Review: Antibiotics for persistent cough or wheeze following acute bronchiolitis in children

Visit

McCallum GB, Morris PS, Chang AB.

McCallum GB, Morris PS, Chang AB.

Objectives: To determine the effectiveness of antibiotics compared to a control (no treatment or placebo) for persistent respiratory symptoms (within six months), following acute bronchiolitis.

Objectives: To determine the effectiveness of antibiotics compared to a control (no treatment or placebo) for persistent respiratory symptoms (within six months), following acute bronchiolitis.

Cochrane Systematic Review: Heliox inhalation therapy for bronchiolitis in infants

Cochrane Systematic Review: Heliox inhalation therapy for bronchiolitis in infants

Visit

Liet JM, Ducruet T, Gupta V, Cambonie G.

Liet JM, Ducruet T, Gupta V, Cambonie G.

Objectives: To assess heliox in addition to standard medical care for acute bronchiolitis in infants.

Objectives: To assess heliox in addition to standard medical care for acute bronchiolitis in infants.

Cochrane Systematic Review: Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children

Cochrane Systematic Review: Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children

Visit

Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B.

Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B.

Objectives: To assess the effectiveness and safety of palivizumab prophylaxis compared with placebo, or another type of prophylaxis, in reducing the risk of complications (hospitalisation due to RSV infection) in high-risk infants and children. To assess the cost-effectiveness (or cost-utility) of palivizumab prophylaxis compared with no prophylaxis in infants and children in different risk groups.

Objectives: To assess the effectiveness and safety of palivizumab prophylaxis compared with placebo, or another type of prophylaxis, in reducing the risk of complications (hospitalisation due to RSV infection) in high-risk infants and children. To assess the cost-effectiveness (or cost-utility) of palivizumab prophylaxis compared with no prophylaxis in infants and children in different risk groups.

Cochrane Systematic Review: Ribavirin for respiratory syncytial virus infections of the lower respiratory tract in infants and young children

Cochrane Systematic Review: Ribavirin for respiratory syncytial virus infections of the lower respiratory tract in infants and young children

Visit

Ventre K, Randolph A.

Ventre K, Randolph A.

Objectives: The objective of this review is to assess the efficacy of aerosolized ribavirin for infants and children with lower respiratory tract infections due to RSV.

Objectives: The objective of this review is to assess the efficacy of aerosolized ribavirin for infants and children with lower respiratory tract infections due to RSV.

Cochrane Systematic Review: Antibiotics for persistent cough or wheeze following acute bronchiolitis in children

Cochrane Systematic Review: Antibiotics for persistent cough or wheeze following acute bronchiolitis in children

Visit

McCallum GB, Morris PS, Chang AB.

McCallum GB, Morris PS, Chang AB.

Objectives: To determine the effectiveness of antibiotics compared to a control (no treatment or placebo) for persistent respiratory symptoms (within six months), following acute bronchiolitis.

Objectives: To determine the effectiveness of antibiotics compared to a control (no treatment or placebo) for persistent respiratory symptoms (within six months), following acute bronchiolitis.